keyword
MENU ▼
Read by QxMD icon Read
search

5-fluorouracil

keyword
https://www.readbyqxmd.com/read/29790787/colorectal-liver-metastases-a-pathologist-s-guide-to-creating-an-informative-report-and-improving-patient-care
#1
Mariana Moreno Prats, Eizaburo Sasatomi, Heather L Stevenson
CONTEXT: - In this era of minimally invasive procedures for diagnosis, prognosis, and treatment, pathologists are at the forefront of analyzing specimens and are expected to make more specific diagnoses, providing additional information from the material they receive. OBJECTIVE: - To familiarize pathologists with the essential components of surgical pathology reports for colorectal liver metastases (CRLM) resections. DATA SOURCES: - Colorectal cancer is the third most common cancer in the world and the liver is the most frequent site of metastases...
May 23, 2018: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29789827/effect-of-the-monostearate-monopalmitate-ratio-on-the-oral-release-of-active-agents-from-monoacylglycerol-organogels
#2
F R Lupi, V Mancina, N Baldino, O I Parisi, L Scrivano, D Gabriele
The delivery of active agents from organogels is becoming an important topic owing to the possibility of releasing, in a controlled way, lipophilic agents. Controlled release from foods is a topic with increasing relevance owing to the growing industrial interest towards functional or medical foods, i.e. foods containing nutraceutical agents or drugs. Anyway, release properties are related to the rheological properties of organogels, and, therefore, a deep knowledge of their microstructure and physical characteristics is necessary to design carriers with expected release properties...
May 23, 2018: Food & Function
https://www.readbyqxmd.com/read/29789423/atp-binding-cassette-member-b5-abcb5-promotes-tumor-cell-invasiveness-in-human-colorectal-cancer
#3
Qin Guo, Tanja Grimmig, Gabriel Gonzalez, Anita Giobbie-Hurder, Gretchen Berg, Nolan Carr, Brian J Wilson, Pallavi Banerjee, Jie Ma, Jason S Gold, Bisweswar Nandi, Qin Huang, Ana Maria Waaga-Gasser, Christine G Lian, George F Murphy, Markus H Frank, Martin Gasser, Natasha Y Frank
ATP-binding cassette member B5 (ABCB5) mediates multidrug resistance (MDR) in diverse malignancies and confers clinically relevant 5-fluorouracil resistance to CD133-expressing cancer stem cells (CSCs) in human colorectal cancer (CRC). Because of its recently identified roles in normal stem cell maintenance, we hypothesized that ABCB5 might also serve MDR-independent functions in CRC. Here, in a prospective clinical study of 142 CRC patients, we found that ABCB5 mRNA transcripts previously reported not to be significantly expressed in healthy peripheral blood mononuclear cells are significantly enriched in patient peripheral blood specimens compared with non-CRC controls and correlate with CRC disease progression...
May 22, 2018: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29785331/nodular-basal-cell-carcinoma-of-the-face-successfully-treated-with-ingenol-mebutate-0-015-gel
#4
Silvia S Iannazzone, Vito Ingordo
Surgical excision is the first-choice treatment for basal cell carcinoma (BCC). Other treatments with topical agents such as 5-fluorouracil or imiquimod have also been suggested for use in superficial BCC (sBCC). Ingenol mebutate (IM) is a novel agent employed in the treatment of superficial actinic keratoses. The drug has been also successfully used in the treatment of sBCC. A case of large nodular BCC (nBCC) of the face in a 100-year-old inoperable woman is described. IM 0.015% gel was applied once daily for three consecutive days...
April 2018: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/29782360/a-phase-ii-study-of-celecoxib-with-irinotecan-5-fluorouracil-and-leucovorin-in-patients-with-previously-untreated-advanced-or-metastatic-colorectal-cancer
#5
Emerson Y Chen, Charles D Blanke, Daniel G Haller, Al B Benson, Tomislav Dragovich, Heinz-Josef Lenz, Carlos Robles, Hong Li, Motomi Mori, Nora Mattek, Rachel E Sanborn, Charles D Lopez
OBJECTIVE: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Cyclooxygenase-2 (COX-2) overexpression is associated with increased tumor invasiveness and proliferation in CRC, and COX-2 inhibition has demonstrated chemopreventive activity. This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC. PATIENTS AND METHODS: Forty-seven patients enrolled in this single-arm phase II study received celecoxib at 400 mg orally twice daily in combination with weekly irinotecan (125 mg/m), 5-fluorouracil (500 mg/m), and leucovorin (20 mg/m) for 4 weeks every 6 weeks...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29781107/pristimerin-targeting-nf-%C3%AE%C2%BAb-pathway-inhibits-proliferation-migration-and-invasion-in-esophageal-squamous-cell-carcinoma-cells
#6
Yuanqing Tu, Fuxing Tan, Jingfeng Zhou, Jingxuan Pan
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer-related death with poor prognosis in China. Identifying novel targeted therapies in ESCC is urgently needed. The aberrant activation of NF-κB signalling pathway is critical for prognosis and recurrence of ESCC, which make it a potential target in the treatment of ESCC. Here, we found that pristimerin inhibited ESCC cell proliferation, migration, invasion, induced cell apoptosis, and eliminated cancer stem-like cells (CSCs). It also showed a synergistic effect on ESCC when combined with 5-fluorouracil (5-FU)...
May 20, 2018: Cell Biochemistry and Function
https://www.readbyqxmd.com/read/29778788/maintaining-dose-intensity-of-adjuvant-chemotherapy-in-older-patients-with-breast-cancer
#7
Rahul Ladwa, Timothy Kalas, Shivanshan Pathmanathan, Natasha Woodward, David Wyld, Jasotha Sanmugarajah
INTRODUCTION: Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain the optimal RDI for standard chemotherapy regimens. The present study investigated the RDI of newer adjuvant chemotherapy regimens in this demographic. PATIENTS AND METHODS: We retrospectively analyzed the data from 281 patients aged ≥ 65 years with a diagnosis of ESBC who had received adjuvant chemotherapy across 3 sites in Queensland, Australia from 2010 to 2015...
April 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29777330/down-regulating-il-6-gp130-targets-improved-the-anti-tumor-effects-of-5-fluorouracil-in-colon-cancer
#8
Sanhong Li, Jilai Tian, Hongming Zhang, Shoubing Zhou, Xiyong Wang, Lei Zhang, Jiapeng Yang, Zhigang Zhang, Zhenling Ji
Recent studies have confirmed that IL-6/GP130 targets are closely associated with tumor growth, metastasis and drug resistance. 5-Fluorouracil (5-FU) is the most common chemotherapeutic agent for colon cancer but is limited due to chemoresistance and high cytotoxicity. Bazedoxifene (BZA), a third-generation selective estrogen receptor modulator, was discovered by multiple ligand simultaneous docking and drug repositioning approaches to have a novel function as an IL-6/GP130 target inhibitor. Thus, we speculated that in colon cancer, the anti-tumor efficacy of 5-FU might be increased in combination with IL-6/GP130 inhibitors...
May 18, 2018: Apoptosis: An International Journal on Programmed Cell Death
https://www.readbyqxmd.com/read/29774120/carboplatin-in-combination-with-weekly-paclitaxel-as-first-line-therapy-in-patients-with-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-unfit-to-extreme-schedule
#9
Adeline Pêtre, Cécile Dalban, Andy Karabajakian, Eve-Marie Neidhardt, Pierre Eric Roux, Marc Poupart, Sophie Deneuve, Philippe Zrounba, Jérome Fayette
The standard first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma combines Cisplatin, 5 Fluorouracil and Cetuximab, but many patients aren't eligible. We retrospectively evaluated the efficacy and the tolerability of Carboplatin and Paclitaxel in this indication, mostly in patients unfit to Cisplatin. Paclitaxel (80mg/m2) was administered at day 1, 8 and 15 and Carboplatin area under the curve 5 at day 1, repeated every 28 days, for 6 cycles. Carboplatin could be administered at area under the curve 2 at day 1, 8 and 15...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29772519/p53-and-p-glycoprotein-influence-chemoresistance-in-hepatocellular-carcinoma
#10
ShengLei Li, Ming Gao, ZongMing Li, LiJie Song, XianZheng Gao, Jing Han, Feng Wang, YongFang Chen, WenCai Li, JianPing Yang
Chemoresistance is a critical obstacle to the treatment of hepatocellular carcinoma (HCC). The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). p53 plays a role in cell growth; therefore, resistance mechanisms involve chemotherapy-induced apoptosis and p53 mutation and inactivation. P-gp is an energy-dependent drug efflux pump regulated by p53. Its role in drug resistance has provided new insights into the mechanisms underlying the involvement of p53 and P-gp in chemoresistance and may alter our traditional understanding of p53 and P-gp function...
June 1, 2018: Frontiers in Bioscience (Elite Edition)
https://www.readbyqxmd.com/read/29771440/mir-519d-reduces-the-5-fluorouracil-resistance-in-colorectal-cancer-cells-by-down-regulating-the-expression-of-ccnd1
#11
R Huang, J-Y Lin, Y-J Chi
OBJECTIVE: To investigate the effects of miR-519d on the 5-fluorouracil resistance in colorectal cancer cells and to explore the mechanism. MATERIALS AND METHODS: Colorectal cancer cells HCT116 and SW480 were transfected with miR519d-mimic or siCCND1 by transient transfection. The sensitivity of cells to 5-Fu was assayed by MTT assay. Dual luciferase assay was used to examine the effect of CCND1 on the sensitivity of cells to 5-Fu mediated by miR-519d. RESULTS: MiR-519d was overexpressed in colorectal cancer cells after transient transfection with miR-519d mimics...
May 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29771107/design-and-synthesis-of-a-biocompatible-1d-coordination-polymer-as-anti-breast-cancer-drug-carrier-5-fu-in-vitro-and-in-vivo-studies
#12
Mahsa Rezaei, Alireza Abbasi, Rassoul Dinarvand, Mahmood Jeddi-Tehrani, Jan Janczak
Designable coordination polymers with suitable chemical diversities and biocompatible structures have been proposed as a promising class of vehicles for drug delivery systems. Here, we hydrothermally synthesized a novel one-dimensional (1D) coordination polymer, [Zn(H2 O)6 K2 (H2 BTC)2 (H2 O)4 ](H2 BTC)2 ·2H2 O, where H3 BTC = benzene-1,3,5-tricarboxylic acid (trimesic acid), cp.1. As the hydrogen bonds stabilized 1D chains in three dimensions, the cp.1 could be a good candidate for delivering small-molecule chemotherapeutics such as 5-fluorouracil (5-Fu)...
May 17, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29769267/functional-characterization-of-21-allelic-variants-of-dihydropyrimidine-dehydrogenase-identified-in-1-070-japanese-individuals
#13
Eiji Hishinuma, Yoko Narita, Sakae Saito, Masamitsu Maekawa, Fumika Akai, Yuya Nakanishi, Jun Yasuda, Masao Nagasaki, Masayuki Yamamoto, Hiroaki Yamaguchi, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka
Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2), encoded by the DPYD gene, is the rate-limiting enzyme in the degradation pathway of endogenous pyrimidine and fluoropyrimidine drugs such as 5-fluorouracil (5-FU). DPD catalyzes the reduction of uracil, thymine, and 5-FU. In Caucasians, DPYD mutations, including DPYD*2A, DPYD*13, c.2846A>T, and 1129-5923C>G/hapB3, are known to contribute to interindividual variations in the toxicity of 5-FU. However, none of these DPYD polymorphisms have been identified in the Asian population...
May 16, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29768350/docetaxel-oxaliplatin-5fu-and-trastuzumab-as-first-line-therapy-in-patients-with-human-epidermal-receptor-2-positive-advanced-gastric-or-gastroesophageal-junction-cancer-preliminary-results-of-a-phase-ii-study
#14
Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion 5-fluorouracil mg/m days 1-5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29768280/phase-i-ii-trial-of-chemotherapy-with-docetaxel-cisplatin-and-s-1-for-unresectable-advanced-squamous-cell-carcinoma-of-the-esophagus
#15
Toshiyasu Ojima, Masaki Nakamura, Mikihito Nakamori, Masahiro Katsuda, Keiji Hayata, Shimpei Maruoka, Toshio Shimokawa, Hiroki Yamaue
Our previous trial with a docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen showed high response rates in metastatic squamous cell carcinoma of the esophagus (SCCE). The observed increased toxicity of the DCF regimen, however, was clinically harmful. S-1, an oral anticancer drug, has been approved as a combination therapy for SCCE, and alternate-day regimen with S-1 has shown lower levels of toxicity. This prospective single-center phase I/II trial examines the efficacy and toxicity of a combination of docetaxel, cisplatin, and an alternate-day regimen of S-1 (modified DCS) for patients with metastatic SCCE...
May 16, 2018: Oncology
https://www.readbyqxmd.com/read/29767264/elemental-diet-inhibits-pro%C3%A2-inflammatory-cytokine-production-in-keratinocytes-through-the-suppression-of-nf%C3%A2-%C3%AE%C2%BAb-activation
#16
Koji Harada, Tarannum Ferdous, Yoichi Mizukami, Katsuaki Mishima
An elemental diet (ED) has been reported to reduce oral mucositis and dermatitis induced by chemotherapy. However, its molecular mechanism of action as an anti‑inflammatory agent is still unknown. The aim of the present study was to clarify whether ED confers its anti‑inflammatory action via reduction of pro‑inflammatory cytokine production in keratinocytes in vivo and in vitro. We evaluated the efficacy of ED in the treatment of 5‑fluorouracil (5‑FU)‑induced dermatitis of nude mice, and examined the expression of pro‑inflammatory cytokines such as tumor necrosis factor‑α (TNF‑α), interleukin (IL)‑1β and IL‑6 using immunohistochemistry...
May 16, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29767247/comparison-of-the-synergistic-anticancer-activity-of-alpcs4-photodynamic-therapy-in-combination-with-different-low%C3%A2-dose-chemotherapeutic-agents-on-gastric-cancer-cells
#17
Jing Xin, Senhao Wang, Luwei Zhang, Bo Xin, Yulu He, Jing Wang, Sijia Wang, Lijian Shen, Zhenxi Zhang, Cuiping Yao
Limited cellular delivery and internalization efficiency of Al(III) phthalocyanine chloride tetrasulfonic acid (AlPcS4) induce poor penetration ability in cells and a slight photodynamic therapy (PDT) effect on gastric cancer. The combination treatment of AlPcS4/PDT with low‑dose chemotherapeutic agents may provide a promising treatment strategy to increase the weak delivery efficiency of AlPcS4, reducing the dose of chemical agents without reducing efficacy, and improving apoptosis‑inducing abilities, thereby increasing the antitumor effects and decreasing the noxious side effects on gastric cancer...
May 16, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29764506/cardiotoxicity-of-5-fluorouracil-and-capecitabine-in-chinese-patients-a-prospective-study
#18
Jianjun Peng, Chao Dong, Chang Wang, Weihua Li, Hao Yu, Min Zhang, Qun Zhao, Bo Zhu, Jun Zhang, Wenliang Li, Fenghua Wang, Qiong Wu, Wenhao Zhou, Ying Yuan, Meng Qiu, Gong Chen
BACKGROUND: 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date. In the present study, we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5-FU- and capecitabine-associated cardiotoxicity in cancer patients recruited from multiple centers in China...
May 11, 2018: Cancer communications
https://www.readbyqxmd.com/read/29764487/effect-of-induction-chemotherapy-with-cisplatin-fluorouracil-with-or-without-taxane-on-locoregionally-advanced-nasopharyngeal-carcinoma-a-retrospective-propensity-score-matched-analysis
#19
Guo-Ying Liu, Xing Lv, Yi-Shan Wu, Min-Jie Mao, Yan-Fang Ye, Ya-Hui Yu, Hu Liang, Jing Yang, Liang-Ru Ke, Wen-Ze Qiu, Xin-Jun Huang, Wang-Zhong Li, Xiang Guo, Yan-Qun Xiang, Wei-Xiong Xia
BACKGROUND: Available data in the literature comparing different induction chemotherapy (IC) regimens on locoregionally advanced nasopharyngeal carcinoma (NPC) are scarce. The purpose of the present study was to evaluate the outcomes of locoregionally advanced NPC patients who were treated with taxane, cisplatin and 5-fluorouracil (TPF) or cisplatin and 5-fluorouracil (PF) as IC followed by concurrent chemoradiotherapy (CCRT). METHODS: In total, 1879 patients with locoregionally advanced NPC treated with IC and CCRT from a prospectively maintained database were included in the present observational study...
May 10, 2018: Cancer communications
https://www.readbyqxmd.com/read/29762717/durable-complete-responses-in-some-recurrent-high-grade-glioma-patients-treated-with-toca-511-toca-fc
#20
Timothy F Cloughesy, Joseph Landolfi, Michael A Vogelbaum, Derek Ostertag, James B Elder, Stephen Bloomfield, Bob Carter, Clark C Chen, Steven N Kalkanis, Santosh Kesari, Albert Lai, Ian Y Lee, Linda M Liau, Tom Mikkelsen, Phioanh Nghiemphu, David Piccioni, William Accomando, Oscar R Diago, Daniel J Hogan, Dawn Gammon, Noriyuki Kasahara, Thian Kheoh, Douglas J Jolly, Harry E Gruber, Asha Das, Tobias Walbert
Background: Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of anti-tumor immunity. Recurrent high grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months...
May 12, 2018: Neuro-oncology
keyword
keyword
100143
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"